Acurx Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Enrollment closed, Enrollment change:  ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov) -  Oct 6, 2023   
    P2b,  N=32, Active, not recruiting, 
    This study highlights the therapeutic potential of IBZ against multidrug-resistant strains of C. difficile. Recruiting --> Active, not recruiting | N=72 --> 32
  • ||||||||||  Review, Journal:  Clostridioides difficile resistance to antibiotics, including post-COVID-19 data. (Pubmed Central) -  Aug 29, 2023   
    Resistance to erythromycin (>60-88%), rifampin (>23-55.0%), imipenem (0.6 to?>?78% in a clone), tigecycline (0-<5.0%), and fidaxomicin (0-2%) was also found...New approaches, including biotherapeutics (Rebyota), strains, antibiotics (ridinilazole and ibezapolstat), and monoclonal antibodies/cocktails merit further evaluation...Post-COVID-19 resistance should be separately presented. Some discrepancies between vancomycin and metronidazole results need to be clarified.
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Trial completion date, Trial primary completion date:  ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov) -  Jul 20, 2023   
    P2b,  N=74, Recruiting, 
    Some discrepancies between vancomycin and metronidazole results need to be clarified. Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Oct 2023
  • ||||||||||  Review, Journal:  Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance. (Pubmed Central) -  Jun 2, 2023   
    Today, the pipeline of potential new treatments with these characteristics includes promising compounds such as gepotidacin, zoliflodacin, ibezapolstat, MGB-BP-3, CRS-3123, afabicin and TXA-709, which are currently in clinical trials, and lefamulin, which has been recently approved by FDA and EMA. In this review, we report the chemical synthesis, mode of action, structure-activity relationships, in vitro and in vivo activities as well as clinical data of these eight small molecules listed above.
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Trial completion date, Trial primary completion date:  ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov) -  Feb 1, 2023   
    P2b,  N=74, Recruiting, 
    In this review, we report the chemical synthesis, mode of action, structure-activity relationships, in vitro and in vivo activities as well as clinical data of these eight small molecules listed above. Trial completion date: Feb 2023 --> Aug 2023 | Trial primary completion date: Dec 2022 --> May 2023
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Ibezapolstat; Acurx Pharmaceuticals (145 AB) -  Jul 23, 2022 - Abstract #IDWeek2022IDWEEK_100;    
    This novel omics approach may allow for better and earlier prediction of anti-CDI recurrence effects for antibiotics in the clinical development pipeline. Sponsored by Acurx Pharmaceuticals
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Trial completion date, Trial primary completion date:  ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov) -  Jun 10, 2022   
    P2b,  N=74, Recruiting, 
    Sponsored by Acurx Pharmaceuticals Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Enrollment open, Trial completion date, Trial primary completion date:  ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov) -  Dec 17, 2021   
    P2b,  N=74, Recruiting, 
    Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Jun 2022 --> Dec 2022 Active, not recruiting --> Recruiting | Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov) -  Dec 19, 2020   
    P2b,  N=74, Active, not recruiting, 
    This hypothesis is being tested in a Phase 2 CDI trial of ibezapolstat Recruiting --> Active, not recruiting | N=20 --> 74 | Trial completion date: Sep 2021 --> Mar 2022 | Trial primary completion date: Jul 2021 --> Dec 2021
  • ||||||||||  Review, Journal:  Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI). (Pubmed Central) -  Nov 1, 2020   
    Various emerging potential therapies with narrow spectrum of activity and little systemic absorption that are in development include 1) Ibezapolstat (formerly ACX-362E), MGB-BP-3, and DS-2969b-targeting bacterial DNA replication, 2) CRS3213 (REP3123)-inhibiting toxin production and spore formation, 3) ramizol and ramoplanin-affecting bacterial cell wall, 4) LFF-571-blocking protein synthesis, 5) Alanyl-L-Glutamine (alanylglutamine)-inhibiting damage caused by C. difficile by protecting intestinal mucosa, and 6) DNV3837 (MCB3681)-prodrug consisting of an oxazolidinone-quinolone combination that converts to the active form DNV3681 that has activity in vitro against C. difficile. This review article provides an overview of these developing drugs that can have potential role in the treatment of rCDI and in lowering recurrence rates.
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Review, Journal:  Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. (Pubmed Central) -  Sep 24, 2020   
    The recent entry of this new class into human trials may herald the introduction of novel drugs whose novel molecular target precludes cross-resistance with existing antibiotic classes. This review therefore examines the evolution of DNA pol IIIC inhibitors from the discovery of 6-(p-hydroxyphenylazo)uracil (HPUra) in the 1960s to the development of current first-in-class N7-substituted guanine drug candidate ACX-362E, now under clinical development for the treatment of Clostridioides difficile infection.
  • ||||||||||  ibezapolstat (ACX-362E) / Acurx Pharma
    Enrollment open:  ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov) -  Mar 10, 2020   
    P2b,  N=20, Recruiting, 
    This review therefore examines the evolution of DNA pol IIIC inhibitors from the discovery of 6-(p-hydroxyphenylazo)uracil (HPUra) in the 1960s to the development of current first-in-class N7-substituted guanine drug candidate ACX-362E, now under clinical development for the treatment of Clostridioides difficile infection. Not yet recruiting --> Recruiting